Have any questions?

Zarqa’s Neuro Panel

About Neuro

Welcome to Zarqa Genomics Lab (ZGL), your trusted ally in unravelling the mysteries encoded within your patients’ DNA. As a premier genomics laboratory, we specialize in the sequencing and interpretation of genomic data to provide unprecedented medical insights.

Our Services

Whole exome sequencing (WES)

presents a comprehensive approach, meticulously sequencing the exons of all protein-coding genes alongside thousands of known disease-causing variants. Despite representing only 1-2% of the human genome, the exome harbours approximately 85% of known disease-related variants.

Whole genome sequencing (WGS)

stands as an advanced genetic analysis technique gaining recognition as the preferred first-line genetic test in routine clinical settings. It transcends the limitations of targeted tests by encompassing coding and non-coding regions, along with mitochondrial DNA (mtDNA), thus offering a holistic view of your patients’ genetic landscape and optimizing diagnostic value.

Features

  • Transform Patient Management: Diagnostic findings can yield tangible changes in patient management.
  • Shorten Diagnostic Journey: It holds significant potential in curtailing the diagnostic odyssey for neonates and paediatric patients with suspected genetic diseases.
  • Cost-Effective Solution: as a primary diagnostic tool, offers cost-effective solutions for patients suspected of rare diseases compared to alternative genetic tests.

Who Can Benefit?

  • Patients with broad, unspecific, or overlapping phenotypic features suggestive of potential Neurogenetic disorders.
  • Pediatric patients presenting with complex clinical features indicative of underlying genetic conditions affecting the Nervous system.
  • Patients manifesting complex symptoms indicative of multiple underlying Neurological conditions, requiring thorough genetic scrutiny.
  • Healthy individuals interested in obtaining carrier status information for family planning purposes, particularly in the context of potential neurological genetic disorders.

Unveiling the Genetic Basis:
A Molecular Atlas of Neurological Disorders

Huntington's disease (HD)

NGS delves into the HTT gene, deciphering CAG repeat expansions as indicative of HD.

Neurofibromatosis (NF)

Identification of mutations in the NF1 gene offers insights into NF-related manifestations.

Fragile X Syndrome (FXS)

NGS scrutinizes the FMR1 gene for CGG repeat expansions, a hallmark of FXS.

Rett Syndrome (RTT)

MECP2 gene mutations serve as diagnostic markers for RTT

Ataxia

Genes such as ATXN1, ATXN2, and ATXN3 undergo thorough analysis for their association with ataxic manifestations.

Amyotrophic Lateral Sclerosis (ALS)

NGS explores mutations in genes like SOD1, C9orf72, and FUS, contributing to ALS pathology.

Autism Spectrum Disorders (ASD)

Genetic variations in numerous genes linked to ASD, decoded through NGS, offer comprehensive insights.

Dementia

Genetic markers within APP, PSEN1, and PSEN2 genes illuminate familial forms of dementia under NGS scrutiny.

Dystonia

Genes like TOR1A, THAP1, and GNAL become subjects of genetic investigations for dystonic manifestations.

Additional Services

Non-Invasive Prenatal Testing (NIPT), Genetic Carrier Screening, BRACA1/ BRACA2 Gene Panel, Paternity Testing, Sanger Sequencing Validation, Genetic Counseling, services of clinical scientist for choosing test, analyses on raw data, reanalyses on analysed report for deeper insights.

Sample types: saliva, blood, DBS cards, isolated DNA

TAT: All samples are processed within 45 working days
Zarqa Genomics is committed to empowering healthcare professionals like you with invaluable genetic insights to enhance patient care and improve health outcomes. Partner with us on the journey to personalized medicine and transformative healthcare solutions.